Careers  |  Sign In  |  Register

Top Selling U.S. Drug Receives Makeover in India

According to Reuters, Indian drug company Cadila Healthcare Ltd has released the first biosimilar form of the anti-inflammatory Adalimumab, the world’s top-selling drug. Also known as Humira, the medication sells for $1,000 a vial in the U.S, compared to its Indian counterpart which sells at just $200 a vial. The medication will go by the name Exemptia, and is expected to reach the U.S. market by 2019.

Read the article published by Reuters.